JP2017538104A - 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用 - Google Patents

癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用 Download PDF

Info

Publication number
JP2017538104A
JP2017538104A JP2017518455A JP2017518455A JP2017538104A JP 2017538104 A JP2017538104 A JP 2017538104A JP 2017518455 A JP2017518455 A JP 2017518455A JP 2017518455 A JP2017518455 A JP 2017518455A JP 2017538104 A JP2017538104 A JP 2017538104A
Authority
JP
Japan
Prior art keywords
biomarker
sample
cancer
level
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017518455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017538104A5 (enExample
Inventor
ロペズ‐ジロナ アントニア
ロペズ‐ジロナ アントニア
イー．キャザース ブライアン
イー．キャザース ブライアン
ル ガング
ル ガング
ジャクソン ピルグリム
ジャクソン ピルグリム
宏 半田
宏 半田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/068795 external-priority patent/WO2015085172A2/en
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2017538104A publication Critical patent/JP2017538104A/ja
Publication of JP2017538104A5 publication Critical patent/JP2017538104A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017518455A 2014-10-07 2015-10-06 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用 Pending JP2017538104A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462061050P 2014-10-07 2014-10-07
US62/061,050 2014-10-07
US201462087111P 2014-12-03 2014-12-03
US62/087,111 2014-12-03
PCT/US2014/068795 WO2015085172A2 (en) 2013-12-06 2014-12-05 Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
USPCT/US2014/068795 2014-12-05
PCT/US2015/054227 WO2016057503A1 (en) 2014-10-07 2015-10-06 Use of biomarkers for predicting clinical sensitivity to cancer treatment

Publications (2)

Publication Number Publication Date
JP2017538104A true JP2017538104A (ja) 2017-12-21
JP2017538104A5 JP2017538104A5 (enExample) 2018-11-29

Family

ID=55653639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518455A Pending JP2017538104A (ja) 2014-10-07 2015-10-06 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用

Country Status (4)

Country Link
US (1) US20180267043A1 (enExample)
EP (1) EP3204008A4 (enExample)
JP (1) JP2017538104A (enExample)
WO (1) WO2016057503A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510816A (ja) * 2018-01-12 2021-04-30 セルジーン コーポレイション セレブロン改変化合物のスクリーニング方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US12466816B2 (en) 2019-09-12 2025-11-11 Shanghaitech University Fused cyclic compound capable of degrading protein and use thereof
WO2021179084A1 (en) * 2020-03-11 2021-09-16 University Health Network Methods and systems for determining a stem cell type in a glioblastoma
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
CN112980882A (zh) * 2021-03-15 2021-06-18 上海科技大学 Crbn基因在构建GSPT1敏感模型中的用途
CN113046391A (zh) * 2021-03-22 2021-06-29 上海科技大学 一种crbn基因人源化动物肿瘤细胞模型的构建方法和用途
US20240255510A1 (en) * 2021-05-10 2024-08-01 The Cleveland Clinic Foundation Salivary metabolites are non-invasive biomarkers of hcc
WO2023115065A2 (en) * 2021-12-17 2023-06-22 Allen Institute Molecular signatures for cell typing and monitoring immune health

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086915A2 (en) * 2005-05-12 2007-08-02 Applied Genomics, Inc. Reagents and methods for use in cancer diagnosis, classification and therapy
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
MX2009001989A (es) * 2006-08-30 2009-03-09 Celgene Corp Compuestos de isoindolina 5-substituidos.
US8877780B2 (en) * 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US20100190656A1 (en) * 2008-08-08 2010-07-29 Integrated Diagnostics, Inc. Breast Cancer Specific Markers and Methods of Use
SG195613A1 (en) * 2008-10-29 2013-12-30 Celgene Corp Isoindoline compounds for use in the treatment of cancer
IL288506B2 (en) * 2012-08-09 2023-09-01 Celgene Corp Methods for treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoisoindolin-2-yl)piperidine-2,6-dione
TW201526897A (zh) * 2013-04-17 2015-07-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
JP2018525991A (ja) * 2015-08-12 2018-09-13 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021510816A (ja) * 2018-01-12 2021-04-30 セルジーン コーポレイション セレブロン改変化合物のスクリーニング方法
JP7267289B2 (ja) 2018-01-12 2023-05-01 セルジーン コーポレイション セレブロン改変化合物のスクリーニング方法

Also Published As

Publication number Publication date
WO2016057503A1 (en) 2016-04-14
EP3204008A1 (en) 2017-08-16
US20180267043A1 (en) 2018-09-20
EP3204008A4 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
JP7113942B2 (ja) がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP2019504063A5 (enExample)
JP2017538104A (ja) 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用
KR102299801B1 (ko) 미만성 거대 b-세포 림프종, 다발성 골수종, 및 골수암의 치료를 위한 약물 효능을 결정하는 방법
US10338077B2 (en) Methods for determining drug efficacy for treatment of cancer ration of cereblon associated proteins
KR102718800B1 (ko) 다발성 골수종의 치료 및 4-(4-(4-(((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조니트릴에 대한 바이오마커의 용도
US20170038387A1 (en) Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
JP2017533727A (ja) 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
JP2018525991A (ja) 固形腫瘍の治療方法及び免疫調節療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
KR20230079171A (ko) 전신 홍반성 루푸스의 치료 방법 및 치료법에 대한 임상적 민감도의 예측인자로서의 바이오마커의 용도
HK1195622A (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181005

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191224